Multi‐omics–driven precision medicine

Abstract Precision medicine is increasingly constrained not by a lack of molecular data but by the absence of frameworks that can translate multidimensional biological information into actionable clinical decisions. Multi‐omics‐driven precision medicine (MODPM) addresses this lack by integrating genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome, and clinical context into a multiscale framework that links molecular mechanisms, tissue organization, and patient trajectories. In this review, we propose a conceptual framework for MODPM and examine how advances in multi‐omics technologies, artificial intelligence (AI), and foundation models are reshaping disease modeling, drug development, and precision intervention. We summarize the biological contributions of major omics layers and discuss how AI supports cross‐modal representation learning, contextual modeling, and perturbation‐aware prediction. We highlight drug development as a key translational application of MODPM and further discuss its clinical relevance across three major disease contexts: cancer, autoimmune diseases, and metabolic disorders, including cardiometabolic and renal–metabolic diseases. These examples illustrate how MODPM can support target discovery, disease endotyping, treatment response prediction, and clinical monitoring by analyzing shared mechanisms such as immune dysregulation, metabolic remodeling, chronic inflammation, tissue microenvironmental changes, and gene–environment interactions. Across these settings, MODPM enables finer molecular stratification, the identification of pathway‐dominant disease states, improved response prediction, and dynamic treatment monitoring. We also discuss key barriers to implementation, including data heterogeneity, limited cohort diversity, polygenic complexity, workflow constraints, cost, and ethical issues related to privacy, consent, and data ownership. Overall, the value of MODPM lies not in stacking additional data layers but in building a multiscale, continuously learnable framework to link biological heterogeneity to clinically interpretable and actionable decisions.

Authors

Institutions

Publication Details

Journal
iMeta
Published
2026-08-25
DOI
https://doi.org/10.1002/imt2.70165
Primary Topic
Genetic Associations and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Multi‐omics–driven precision medicine

Zhe Zhao, Wei Hu, Gaofei Hu, Chao Zhong et al.
iMeta
Genetic Associations and Epidemiology
article

Multi‐omics–driven precision medicine

Zhe Zhao, Wei Hu, Gaofei Hu, Chao Zhong, Huibo Li, Hairong Lv, Yi Zhun Zhu, Lemin Zheng, Yao Ma, Min Zeng, Yifan Zhang, Matthew Whiteman, Jun Li, Zhanqun Yang, Zixuan Zhao, Wei Fu, Yuxuan Sun, Meng Su, Long Chen, Xin Zhou, Rongsheng Zhao
article en

Abstract

Abstract Precision medicine is increasingly constrained not by a lack of molecular data but by the absence of frameworks that can translate multidimensional biological information into actionable clinical decisions. Multi‐omics‐driven precision medicine (MODPM) addresses this lack by integrating genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiome, and clinical context into a multiscale framework that links molecular mechanisms, tissue organization, and patient trajectories. In this review, we propose a conceptual framework for MODPM and examine how advances in multi‐omics technologies, artificial intelligence (AI), and foundation models are reshaping disease modeling, drug development, and precision intervention. We summarize the biological contributions of major omics layers and discuss how AI supports cross‐modal representation learning, contextual modeling, and perturbation‐aware prediction. We highlight drug development as a key translational application of MODPM and further discuss its clinical relevance across three major disease contexts: cancer, autoimmune diseases, and metabolic disorders, including cardiometabolic and renal–metabolic diseases. These examples illustrate how MODPM can support target discovery, disease endotyping, treatment response prediction, and clinical monitoring by analyzing shared mechanisms such as immune dysregulation, metabolic remodeling, chronic inflammation, tissue microenvironmental changes, and gene–environment interactions. Across these settings, MODPM enables finer molecular stratification, the identification of pathway‐dominant disease states, improved response prediction, and dynamic treatment monitoring. We also discuss key barriers to implementation, including data heterogeneity, limited cohort diversity, polygenic complexity, workflow constraints, cost, and ethical issues related to privacy, consent, and data ownership. Overall, the value of MODPM lies not in stacking additional data layers but in building a multiscale, continuously learnable framework to link biological heterogeneity to clinically interpretable and actionable decisions.

iMeta
Macau University of Science and Technology (MO), Peking University (CN), University of Macau (MO), University of Exeter (GB), Fudan University (CN), Peking University Cancer Hospital (CN), Zhuhai People's Hospital (CN), Tianjin Children's Hospital (CN), Peking University First Hospital (CN), Peking University Third Hospital (CN), University of Louisiana at Monroe (US), Tsinghua University (CN)
Openalex Percentile: Top 10%
Genetic Associations and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.